News >

FDA Panel to Review Blinatumomab Application for MRD-positive ALL

Jason Harris
Published: Thursday, Feb 15, 2018

David M. Reese, MD

David M. Reese, MD
The FDA’s Oncologic Drugs Advisory Committee (ODAC) is slated to review a supplemental biologics license application (sBLA) for the use of blinatumomab (Blincyto) for the treatment of patients with minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL).

David M. Reese, MD, Amgen senior vice president of Translational Sciences and Oncology, said in a press release that this is the first sBLA submitted for an MRD-positive indication.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication